Retreat Doctors' Hospital
October 24, 2017

Richmond, Va. – HCA Virginia’s Retreat Doctors’ Hospital offers innovative treatment option for prostate disease. The hospital recently participated in a national clinical trial with PROCEPT BioRobotics, a Silicon Valley robotics company developing intelligent surgical solutions to treat prostate disease.

Eugene Kramolowsky, M.D., board-certified urologist with Virginia Urology, is the first surgeon in the state of Virginia to perform aquablation therapy, which enables targeted, controlled, heat-free and immediate removal of prostate tissue for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH).

“Aquablation is a promising technology for patients with BPH, a common prostate problem affecting 50 percent of men between the ages of 51 and 60,” said Dr. Kramolowsky. “We are proud to offer a minimally invasive alternative to open prostatectomy and are encouraged by the results of the WATER Study. “BPH is a very common condition in older men and we look forward to exploring the potential benefits of this treatment option.”

Retreat Doctors’ Hospital was the first hospital in the State of Virginia to participate in the study, which was designed to improve treatment options for men with BPH.

The WATER II Study, Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II, is a U.S. clinical trial that evaluates the safety and efficacy of aquablation for the treatment of benign prostatic hyperplasia (BPH).

Retreat Doctors’ Hospital is one of 20 sites in the United States and Canada participating in the study.

About HCA Virginia

As the commonwealth’s most comprehensive provider network, HCA Virginia Health System operates 13 hospitals and 30 outpatient centers and is affiliated with 3,000 physicians. It is one of Virginia’s largest employers, provides $365 million in uncompensated care and pays $72 million in state and local taxes each year. HCA Virginia includes 6 imaging centers, 6 outpatient surgery centers, three freestanding emergency rooms, and 7 hospitals – Chippenham, Henrico Doctors’, John Randolph, Johnston-Willis, Parham Doctors’, Retreat Doctors’ and Spotsylvania Regional.

Virginia Urology (VU) has been providing quality care to the Greater Richmond metro area for over 80 years. VU prides itself on its strong commitment to the community’s urological needs by recruiting highly skilled physicians and using the latest technology. The practice is comprised of over 40 physicians including urologists, urogynecologists and physicians specializing in the urologic aspect of anesthesiology, pathology, radiation oncology, and radiology. VU has 7 office locations throughout the Greater Richmond area and 2 licensed and accredited ambulatory surgery centers.

About Benign Prostatic Hyperplasia (BPH)

BPH is a common prostate problem affecting about 50 percent of men between the ages of 51 and 60 and up to 90 percent of men older than 80. As many as 20 million men in the United States have lower urinary tract symptoms suggestive of BPH. While effective for some, BPH medications are typically only used to treat mild to moderate symptoms and are associated with bothersome side effects including retrograde ejaculation and other sexual side effects, as well as nausea and dizziness. The most common surgical procedures to treat BPH today are transurethral resection of the prostate (TURP) and laser therapy, both of which utilize heat to remove the enlarged prostate tissue. These surgical methods are successful at removing the enlarged tissue but have been shown to have significant complications.

About PROCEPT BioRobotics

Based in Silicon Valley, PROCEPT BioRobotics is enabling better patient care by developing robotic surgical solutions to treat prostate disease. With an initial focus on benign prostatic hyperplasia (BPH), the company has developed the AQUABEAM System, which leverages the company’s core Aquablation technology. Aquablation is a precise and controlled waterjet ablation therapy that enables heat-free and immediate removal of prostate tissue. The AQUABEAM System is available for investigational use only in the U.S. and not currently available for sale in the U.S. or Canada. The AQUABEAM System has received CE Mark certification and is available in select global markets.